Endo Inc., formed as a result of Malvern-based Endo International’s bankruptcy reorganization plan, has finalized the acquisition of most of the assets of its predecessor, writes John George for the Philadelphia Business Journal.
Now that it has emerged from bankruptcy, the specialty pharmaceutical company with a manufacturing plant in Horsham is focusing on the future.
According to Blaise Coleman, Endo’s CEO, the company will concentrate on expanding its branded pharmaceuticals segment, anchored by Xiaflex, as well as on reviving its sterile injectables segment by launching “differentiated” new products.
Endo, which is currently a privately held company, has also already started the process of listing its equity on a national stock exchange. The process is expected to be finalized later in the year.
Xiaflex, which is Endo’s flagship product, generated sales of $475 million last year. The medicine is approved by the Food and Drug Administration to treat Dupuytren’s contracture and Peyronie’s disease.
Coleman said that Endo also plans on “leveraging its improved balance sheet to drive new growth investments,” as the new entity is now operating with significantly reduced outstanding debt.
Read more about Endo Inc.’s plans after bankruptcy in the Philadelphia Business Journal.
_____
